Nov 4, 4:13 PM ET
Acadia reported third-quarter 2026 GAAP total revenues of $342 million, up 23% from a year earlier, with DAYBUE net sales up 39% to $140 million. Net income fell to $54 million, or $0.31 per diluted share, from $72 million, or $0.42, a year earlier. The company raised its 2026 DAYBUE net sales guidance and narrowed its total revenue range, while lowering its R&D expense guidance.
- Q3 2026 GAAP total revenues were $342 million, up from $279 million in Q3 2025; NUPLAZID net sales were $202 million and DAYBUE net sales were $140 million.
- Q3 2026 net income was $54 million, or $0.31 per diluted share, versus $72 million, or $0.42 per diluted share, in Q3 2025.
- 2026 DAYBUE net sales guidance raised to $505 to $520 million from $480 to $510 million; total revenue guidance narrowed to $1.265 to $1.295 billion from $1.24 to $1.30 billion.
- Cash, cash equivalents and investment securities were $976 million at September 30, 2026, up from $820 million at December 31, 2025.
Read the filing on SEC.gov ↗
Oct 23, 4:51 PM ET
Acadia Pharmaceuticals said Elizabeth H.Z. Thompson, its Executive Vice President and Head of Research and Development, is retiring from her employee role effective October 23, 2026. She will remain with the company as a consultant, providing limited services through December 31, 2026, and the company is searching for a replacement.
- Dr. Elizabeth H.Z. Thompson informed the company of her planned retirement on April 27, 2026, for personal reasons
- Effective October 23, 2026, she no longer serves as an employee or as Head of Research and Development
- She will be retained as a consultant and intends to provide limited consulting services through December 31, 2026
- The company is in the process of identifying a replacement Head of Research and Development
Read the filing on SEC.gov ↗
Aug 4, 4:16 PM ET
Acadia Pharmaceuticals reported second-quarter 2026 GAAP total revenues of $308 million, up 16% from a year earlier, and net income of $32 million, or $0.18 per diluted share, compared with $27 million, or $0.16, in the same quarter of 2025. The company raised its full-year 2026 total revenue guidance to $1.24 billion to $1.30 billion, and both revenue and profit improved for shareholders in the period.
- Q2 2026 GAAP total revenues were $308 million, up 16% from $265 million; DAYBUE net product sales rose 30% to $125 million.
- Full-year 2026 total revenue guidance was raised to $1.24 billion to $1.30 billion, from $1.22 billion to $1.28 billion.
- Full-year 2026 R&D expense guidance was lowered to $355 million to $380 million, from $385 million to $410 million.
- Cash, cash equivalents and investment securities totaled $956 million at June 30, 2026, up from $820 million at December 31, 2025.
Read the filing on SEC.gov ↗
May 29, 4:05 PM ET
At its May 29, 2026 annual meeting, Acadia Pharmaceuticals stockholders elected three Class I directors, approved an advisory vote on executive compensation, ratified Ernst & Young LLC as auditor for 2026, and approved an amendment to the 2024 Equity Incentive Plan. The amendment increases the shares authorized for issuance under the plan by 5,209,670, which expands the pool available for equity awards.
- Plan amendment adds 5,209,670 authorized shares; approved with 147,258,860 for and 3,096,136 against.
- Directors elected to terms ending at the 2029 annual meeting: James M. Daly (146,927,745 for), Edmund P. Harrigan, M.D. (128,460,130 for), Adora Ndu, Pharm.D., J.D. (134,540,552 for).
- Executive pay approved on an advisory basis with 148,265,173 for and 1,911,358 against.
- Ernst & Young LLC ratified as independent auditor for the fiscal year ending December 31, 2026, with 157,409,378 for.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.